GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma

Sponsor
Glaukos Corporation (Industry)
Overall Status
Completed
CT.gov ID
NCT01052558
Collaborator
(none)
164
22
2
47
7.5
0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of the GTS400 trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.

Condition or Disease Intervention/Treatment Phase
  • Device: iStent Inject (GTS400)
  • Procedure: Cataract Surgery
Phase 3

Detailed Description

Glaucoma is a collection of disorders characterized by progressive loss of visual field due to optic nerve damage. It is a leading cause of blindness in the United States, affecting 1-2% of individuals aged 60 and over. Management of glaucoma requires chronic, life-long treatment with a spectrum of therapeutic options including medications, laser treatment and surgical implants. The common goal among the various therapies is to lower intraocular pressure to target levels in order to prevent loss of visual fields from excessive pressure on the optic nerve.

Study Design

Study Type:
Interventional
Actual Enrollment :
164 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Prospective, Randomized, Controlled, Parallel Groupos, Multicenter Clinical Investigation of the Glaukos Trabecular Micro-bypass Stent Model GTS400 in Conjunction With Cataract Surgery
Study Start Date :
Jan 1, 2010
Actual Primary Completion Date :
Dec 1, 2013
Actual Study Completion Date :
Dec 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Cataract Surgery Only

Procedure: Cataract Surgery
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.

Experimental: Treatment with Cataract Surgery & Stents

Ab interno trabecular micro-bypass stent surgery

Device: iStent Inject (GTS400)
Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
Other Names:
  • Cataract surgery, stent implantation
  • Outcome Measures

    Primary Outcome Measures

    1. Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit. [12 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosed with open-angle glaucoma in the study eye

    • Subject must be on 1 to 3 glaucoma medications

    • Subject able and willing to attend follow up visits for two years postop

    • Subject able and willing to sign informed consent

    Exclusion Criteria:
    • Pseudoexfoliative and pigmentary glaucoma

    • Prior glaucoma surgery of any type

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Boozman-Hof Regional Eye Clinic Rogers Arkansas United States 72756
    2 North Bay Eye Associates, Inc. Petaluma California United States 94954
    3 Glaucoma Consultants of Colorado Parker Colorado United States 80134
    4 The Center for Excellence in Eye Care Miami Florida United States 33176
    5 International Eye Center Tampa Florida United States 33603
    6 Clayton Eye Center / Eye Care Centers Management, Inc. Morrow Georgia United States 30260
    7 Chicago Eye Specialists Chicago Illinois United States 60619
    8 Whitson Vision, PC Indianapolis Indiana United States 46240
    9 D'Ambrosio Eye Care Lancaster Massachusetts United States 01523
    10 Kresge Eye Institute Detroit Michigan United States 48201
    11 Discover Vision Centers Independence Missouri United States 64055
    12 Silverstein Eye Centers Kansas City Missouri United States 64133
    13 St. John's Medical Research Institute Springfield Missouri United States 65807
    14 Las Vegas Physician Research Group Henderson Nevada United States 75965
    15 Shepherd Eye Center Las Vegas Nevada United States 89121
    16 Ophthalmic Consultants of Long Island Rockville Center New York United States 11570
    17 Thomas Mundorf, MD Charlotte North Carolina United States 28204
    18 Laurel Eye Clinic Brookville Pennsylvania United States 15825
    19 Carolina Eyecare Physicians Mt. Pleasant South Carolina United States 29464
    20 Vance Thompson Vision / Sanford Clinic Sioux Falls South Dakota United States 57105
    21 Texan Eye Austin Texas United States 78731
    22 Lehmann Eye Center Nacogdoches Texas United States 75965

    Sponsors and Collaborators

    • Glaukos Corporation

    Investigators

    • Study Director: Jeff Wells, PharmD, MBA, Glaukos Corporation
    • Study Chair: Jay Katz, MD, Wills Eye Institute; Thomas Jefferson University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Glaukos Corporation
    ClinicalTrials.gov Identifier:
    NCT01052558
    Other Study ID Numbers:
    • GC-006
    First Posted:
    Jan 20, 2010
    Last Update Posted:
    May 19, 2015
    Last Verified:
    May 1, 2015
    Keywords provided by Glaukos Corporation
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 19, 2015